A drug already on the market for 20 years effectively reduced nodules associated with Dupuytren's disease in a mid-stage trial, researchers said. Patients receiving intranodular injections of ...

Injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules is effective in reducing nodule hardness and nodule size.

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Eligibility criteria included adults with early-stage Dupuytren’s disease and a clinically distinct nodule with a clear history of progression in the preceding six months.

It is possible to differentiate Dupuytren's disease from other causes of muscle and tissue hardening of the hand since it initiates as a nodule, or lump, and slowly progresses to contracture of ...

Shining the spotlight on a fairly common hand condition that most people have never heard of. It's called Dupuytren's, and it reportedly affects some 200,000 people a year. "It just popped up ...

This randomized trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.

In a new study, scientists show that anti-TNF inhibits the cells responsible for Dupuytren's disease.

Identification of unique miRNA expression in Dupuytren's contracture may lead to the development of novel molecular therapy for its treatment.

Dupuytren’s contracture is a gradual thickening of the connective tissue of the palm of the hand. It may begin innocently as a nodule in the palm or joint stiffness, which are common symptoms ...

The natural history of Dupuytren's contracture can be variable, but there tends to be a slow but steady progression. It generally starts as a nodule in the palm and evolves into cordlike ...